

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

01-057

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/744659

INTERNATIONAL APPLICATION NO.

PCT/FR99/01871

INTERNATIONAL FILING DATE

29 July 1999

PRIORITY DATE CLAIMED

31 July 1998

TITLE OF INVENTION

TRIMER OF HIV ENV GENE EXPRESSION PRODUCT

APPLICANT(S) FOR DO/EO/US

CHEVALIER, Michel

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

Return Receipt Postcard


U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) 09/744659		INTERNATIONAL APPLICATION NO. PCT/FR99/01871		ATTORNEY'S DOCKET NUMBER 01-057	
--	--	--	--	---	--

21. The following fees are submitted:			CALCULATIONS PTO USE ONLY					
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00			<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</td> <td style="text-align: right;">\$860.00</td> </tr> </table>			ENTER APPROPRIATE BASIC FEE AMOUNT =		\$860.00
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$860.00						
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30			<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td style="width:80%;"></td> <td style="text-align: right;">\$130.00</td> </tr> </table>				\$130.00	
	\$130.00							
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE					
Total claims	19 - 20 =	0	x \$18.00	\$0.00				
Independent claims	1 - 3 =	0	x \$78.00	\$0.00				
Multiple Dependent Claims (check if applicable) <input checked="" type="checkbox"/>				\$260.00				
TOTAL OF ABOVE CALCULATIONS =				\$1,250.00				
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input type="checkbox"/>				\$0.00				
SUBTOTAL =				\$1,250.00				
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 +				\$0.00				
TOTAL NATIONAL FEE =				\$1,250.00				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00				
TOTAL FEES ENCLOSED =				\$1,250.00				
				Amount to be:				
				refunded	\$			
				charged	\$			

<input checked="" type="checkbox"/> A check in the amount of \$1,250.00 to cover the above fees is enclosed. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 13-2490 A duplicate copy of this sheet is enclosed.	
--	--

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GREENFIELD, Michael S. McDONNELL BOEHLEN HULBERT & BERGHOFF 300 South Wacker Drive, Suite 3200 Chicago, Illinois 60606 United States of America	 SIGNATURE Michael S. Greenfield NAME 37,142 REGISTRATION NUMBER 25 January 2001 DATE
---	--

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-057)

In the Application of:)
)
 Chevalier)
) Examiner: TBA
 Serial No.: US National Phase of PCT/FR99/01871)
) Group Art Unit: TBA
 Filing Date: Int'l Filing Date July 29, 1999)
)
 For: Trimer of HIV env)
 Gene Expression Product)

PRELIMINARY AMENDMENT

Asst. Commissioner for Patents
 Washington, D.C. 20231

Dear Sir:

Please consider the following amendments and remarks before examination on the merits.

AMENDMENTS**In the specification:**

At page 17, line 22, please delete "(publication?)".

In the claims:

Please cancel claims 1-10 and add the following new claims:

11. (New) A composition comprising a purified trimer of a naturally-occurring or recombinant HIV gp160, wherein the trimer:
 - a) binds to CD4;
 - b) binds to an anti-gp120 antibody capable of neutralizing HIV infection of cells *in vitro*;

- c) binds to an anti-gp41 antibody; and
 - d) has no inter-chain disulfide bridges.
12. (New) The composition according to claim 11, wherein the gp160 comprises a gp41 and a gp120 from different HIV strains.
13. (New) The composition of claim 11, wherein all or a portion of the gp160 transmembrane region is deleted.
14. (New) The composition according to any one of claims 11 - 13 having a protein content that comprises more than 50% of the trimer.
15. (New) The composition according to any one of claims 11 - 13 wherein the binding affinity of the trimer to CD4 is equal or greater than the binding affinity of gp120 of an infectious HIV.
16. (New) A vaccine comprising the composition of any one of claims 11 - 13 and an adjuvant.
17. (New) A vaccine according to claim 16 wherein the trimer is the only HIV surface antigen in the vaccine.
18. (New) A method of producing the trimer according to any one of claims 11 - 13, the method comprising:
- a) expressing gp160 or fragment thereof;
 - b) purifying the gp160;
 - c) contacting the gp160 with a reducing agent;

- d) contacting the gp160 with an alkylating agent;
 - e) contacting the gp160 with an oxidizing agent;
 - f) contacting the gp160 with an ionic detergent, and
 - g) dialyzing the gp160 against a neutral detergent.
19. (New) A method of producing the trimer according to any one of claims 11 - 13, the method comprising:
- a) expressing gp160 or fragment thereof;
 - b) purifying the gp160;
 - c) contacting the gp160 with an ionic detergent;
 - d) contacting the gp160 with a reducing agent;
 - e) contacting the gp160 with an oxidizing agent; and
 - f) dialyzing the gp160 against a neutral detergent.


REMARKS

If there are any questions or comments regarding this Response or application, the Examiner is encouraged to contact the undersigned attorney as indicated below.

Date: January 25, 2001

Telephone: 312-913-0001
Facsimile: 312-913-0002

Respectfully submitted,


Michael S. Greenfield
Registration No. 37,142

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, IL 60606

Trimer of the HIV env gene expression product

The present invention relates to a method for obtaining recombinant proteins, the origin of which is the membrane of the HIV virus responsible for the acquired immunodeficiency syndrome (AIDS), allowing the restoration of their native trimeric form, and to the use of these proteins for the purpose of vaccination or of diagnosis.

State of the art

The HIV envelope glycoprotein is encoded by the "env" gene, and the translation of the corresponding mRNA gives a glycosylated protein, gp160, in the form of a precursor with a molecular mass of 160 kDa. gp160 is cleaved inside the cell to give, at the cytoplasmic membrane during budding of the virus in the process of formation, on the one hand gp120, which is found on the outside of the cell and of the virus, and on the other hand gp41, which is the transmembrane portion of the glycoprotein and which corresponds to the carboxy-terminal end of the precursor. Once the viral particle has been released, gp41, the only transmembrane protein, will have its carboxy-terminal end turned toward the inside of the virus and its amino-terminal end projecting on the outside, maintaining itself associated noncovalently with gp120. It is attached noncovalently to gp41 via its amino-terminal end, while the rest of the protein is involved in the recognition of the CD4 receptor and of the CCR5 or CXCR4 coreceptors (specific for auxiliary T4 lymphocytes, macrophages; Trkola et al., J. Virol., 72, 1876-85, 1998; Schols et al., J. Virol., 72, 4032-4037, 1998; Rubbert et al., J. Immunology, 160, 3933-3941, 1998). The binding of gp120 to CD4 makes it possible to expose the membrane of the target cell to the amino-terminal hydrophobic portion of gp41, thereby inducing the mechanism of fusion of the viral and cell membranes,

this fusion being the cause of the penetration of the virion into the target cell during infection (Wong-Staal et al., In Molecular Genetic Medecine, 2, Friedman ed., 189-219, 1992; Berger et al., Nature, 391: 240, 1998).

This process of recognition of the viral receptor, followed by the fusion of the membranes due to the interaction of the amino-terminal end of the fusion protein with the target cell membrane, is not a mechanism unique to HIV. It is made possible due to the presence, in oligomeric form, of the transmembrane glycoproteins of the virus. Bridging using chemical agents has made it possible to demonstrate trimers within the glycoproteins of the MuLV (Pinter et al., J. Virol., 30, 157-165, 1979), and MuMTV (Racevskis et al., J. Virol., 35, 937-948, 1980) envelope. It has also been shown that the RSV envelope protein forms oligomers which are found in infected cells and viral particles (Einfeld et al., Proc. Natl. Acad. Sci. USA, 85, 8688-8692, 1988). The influenza virus also expresses, at its surface, a haemagglutinin in trimeric form. In the latter case, the multimeric form is required for the intracellular transport of the protein (Copeland et al., J. Cell. Biol., 103, 1179-1191, 1986). The [lacuna] influenza also expresses, at its surface, a neuraminidase in the form of a tetramer (Varghese et al., Nature, 303, 35-40, 1983).

Although there is no doubt about the oligomeric nature of the various proteins encoded by the env gene, the monomer number has, itself, remained a controversial subject for a long time. The gp160 glycoprotein has, in fact, for a long time been described as being able to assemble into dimers or tetramers (Pinter et al., J. Virol., 63, 2674-2679, 1989; WO 94/00557 of the CNRS; Schawaller et al., Virology, 172, 367-369, 1989; Earl et al., Proc. Natl. Acad. Sci., 87, 648-652, 1990; Earl et al., J. Virology, 68, 3015-3026, 1994). Other more recent

reports have, however, demonstrated that gp160 might, in fact, associate naturally, via its gp41 portion, in the form of trimers (Min Lu et al., Nature Structural Biology, 2, 1075-1082, 1995; Weisshorn et al., EMBO J., 15, 1507-1514, 1996; Weisshorn et al., Nature, 387, 426-430, 1997), the dimeric or tetrameric forms resulting, in fact, from aberrant interchain disulphide bridges or from transient oligomeric forms (see below).

For vaccinal purposes, the HIV envelope glycoprotein can be produced and purified, either by culturing the HIV virus on cell lines and purifying the glycoprotein from the culture medium (WO 94/00557 of the CNRS), or by expressing a recombinant of this protein using a vector other than HIV and purifying it from the culture medium (WO 91/13906, Chiron).

The purification of gp160 from cells infected with HIV makes it possible to obtain only tetramers, which is probably a transient oligomeric form, i.e. a form which does not correspond to that taken by its gp41 portion at the surface of the virus (WO 94/00557 of the CNRS).

The expression of a gp160 recombinant using a vector other than HIV, although having the advantage of escaping the dangers linked to the HIV infectious agent, does not make it possible also to have the "native" oligomeric structure of gp160. Specifically, VanCott et al. have shown that the recombinant gp160 expressed by vaccinia, although having the power to adhere to CD4, comprises structural differences (J. Imm. Meth., 183, p. 114, col. 1, li. 19-22, 1995). Randall et al. have also shown that the recombinant gp160 expressed by vaccinia comprises aberrant interchain disulphide bridges (Virology, 179, 827-833, 1990).

Recently, Parren et al. have demonstrated a correlation between the production of antibodies which can neutralize, *in vitro*, HIV infection of cells and the oligomeric nature of gp120 (J. of Virology, 72,

3512-3519, 1998). For this, Parren et al. used a gp120 expressed by HIV in infected cells, probably in order to get round the problems linked to the structural differences between a native gp120, expressed at the surface of HIV, and those produced by expression vectors such as vaccinia.

Moreover, it is known that antibodies specific for the oligomeric structure of gp160 can be generated (Earl et al., above), and participate, in fact, in a neutralizing effect against HIV infection of cells, *in vitro*.

The present invention is directed towards providing a method for obtaining recombinant env gene expression products, which allows the restoration of their trimeric form, this form possibly being used in the context of a vaccination or in carrying out a diagnosis of HIV infection. In fact, the clinical trials carried out on recombinant gp160 molecules pose the problem of the spectrum of inhibition, which remains limited to only a few viral strains (Pialoux et al., Aids Res. Hum. Retr., 11, 373-381, 1995; Salmon-Céron et al., Aids Res. Hum. Retr., 12, 1479-1486, 1995).

To date, although the trimeric form of a gp160 has been identified several times in a mixture of other polymeric forms, no-one has purified, nor suggested purifying, the trimeric form of gp160. The present [lacuna] is aimed at overcoming this need.

Summary of the invention

For this purpose, the invention relates to any purified recombinant glycoprotein which satisfies the following properties:

- a) a capacity for adhesion to CD4;
- b) an affinity with an anti-gp120 antibody capable of neutralizing HIV infection of cells, *in vitro*;
- c) an affinity with an anti-gp41 antibody;

d) a trimeric form lacking interchain disulphide bridges.

A second subject of the present invention relates to a vaccine comprising the purified
5 glycoprotein according to the invention, and an adjuvant.

A third subject of the present invention relates to the use of the glycoprotein according to the invention in the implementation of any method for
10 diagnosing, *in vitro*, infections caused by HIV.

A final subject of the present invention relates to a method for obtaining a glycoprotein according to the invention, in which, by means of genetic recombination techniques, a glycoprotein
15 satisfying the properties a), b) and c) according to the invention is expressed, purified and subjected to steps involving at least one reducing agent, one ionic detergent and/or one neutral detergent, under conditions such that a glycoprotein satisfying the
20 conditions according to the invention is obtained.

Detailed description of the invention

In the context of the present invention, the capacity for adhesion to CD4 can be determined by
25 radio-immune precipitation, by ELISA or by surface plasmon resonance, the detail of these methods being set out in the remainder of the description. These methods can be modified within the limit of current knowledge, the objective being to simply make sure that
30 the glycoprotein according to the invention indeed forms a complex with CD4.

The CD4 molecules can be prepared in all kinds of different ways, including purification from a natural source or using genetic recombination
35 techniques. In this context, it is possible to use the CD4 molecules described in WO 89/03222, WO 89/02922, Smith et al. (Science, 238, 1704-1707, 1987) and Littman et al. (Nature, 325, 453-455, 1987), for

example. The company ERC BioServices Corporation, 649A Lofstrand Lane, Rockville, MD 20850, USA, also sells a CD4 produced by CHO ST4.2 cells (In: Aids Research and Reference Reagent Program Catalog, the Nat. Inst. Health U.S.D.H.H.S.), for example.

Preferably, the capacity for adhesion is at least identical to that of a gp120 of an infectious HIV strain, for example a gp120 originating from the SF2, HXB2, BRU, MN, SC, NY5, CDC4, WMJ2, RF, MAL, ELI, Z96, Z3, Z321 and JY1 5 isolates (Myers et al., Human Retroviruses and Aids, Los Alamos, New Mexico, 1990), or from the other isolates described by Tersmette et al. (J. Virol., 62, 2026-2032, 1988), Popovic et al. (Science, 224, 497-500, 1984), and EP541753 (Transgene S.A.), for example.

The affinity (K_d) measured by surface plasmon resonance can also be of the order of 10^{-4} to 10^{-12} M, preferably 10^{-9} to 10^{-11} M, which is in accordance with the affinities already measured for gp120 molecules (Smith et al., Science, 238: 1704, 1987; Lasky et al., Cell, 50: 975, 1987), for example.

The recombinant glycoprotein according to the invention also has an affinity with an anti-gp120 antibody capable of neutralizing, *in vitro*, HIV infection of cells. The term "antibodies" includes all immunoglobulins or fragments of these immunoglobulins, of polyclonal, monoclonal or chimeric original [sic] (see US4816397), for example. All known antibodies, or antibodies likely to be prepared, capable of recognizing an epitope of gp120 and of neutralizing, *in vitro*, the infection of cells by an HIV may be taken into account in the context of the present invention. In order for an HIV glycoprotein to be considered as satisfying the needs of the present invention, it merely needs to have an affinity with an antibody of this type. Without wishing to be limited by the techniques and antibodies which can be used for the needs of the invention, mention may be made, by way of

information, of the articles by VanCott et al. (1995, above) and Earl et al. (1994, above), for example.

With regard to the assays for measuring the neutralizing efficiency of an antibody *in vitro*,
5 mention may be made of the articles by Pialoux et al. (1995, above) and Salmon-Céron et al. (1995, above), for example. In order to consider that the antibody satisfies the needs of the present invention, neutralization, *in vitro*, of HIV infection of cells
10 merely has to be observed, whatever the neutralization threshold.

Moreover, the recombinant glycoprotein according to the invention also has an affinity with an anti-gp41 antibody. The comments set out above apply
15 *mutatis mutandis* to gp41, with the difference that the neutralizing effect of an anti-gp41 antibody is not important, while at the same time possibly being a preferential criterion not to be ignored.

The measurement of the affinity of the
20 glycoprotein in trimeric form with the anti-gp41 and anti-gp120 antibodies can be carried out through direct immunological reaction with the antibody, or by ELISA, for example. The operating conditions can vary within the limits of current knowledge, the variations and/or
25 adaptations with respect to known techniques not, in fact, representing a difficult obstacle for those skilled in the art.

The trimeric form of the glycoprotein according to the invention can be observed on SDS PAGE gel,
30 possibly under reducing conditions (see Example 1). Those skilled in the art may, however, use any kind of other analyses, such as analytical centrifugation or analysis by light diffusion. The objective is simply to demonstrate the association of three gp160 molecules
35 which are not linked by interchain bridges.

The glycoprotein according to the invention, in satisfying the properties set out above, can therefore be composed of all or part of the gp41 protein, and of

all or part of the gp120 protein. As a result, this glycoprotein can be encoded by all or part of an env gene, which may or may not be native (originating from an HIV isolate), said glycoprotein being either
5 purified at a stage when the cleavage has not yet taken place *in situ*, or said cleavage being made nonfunctional either because of the nature of the cellular host, which does not have the required enzymes, because of inhibitors of these enzymes, or
10 because the cleavage site has been genetically modified, for example.

The genetic modification of the cleavage site is well known to those skilled in the art, and makes it possible to obtain whole proteins, of varying sizes,
15 containing all or part of the gp41 and all or part of the gp41 [sic]. By way of nonlimiting information, mention may be made of the gp160 and gp140 glycoproteins described by EP541753 (above), EP679187 (above), Earl et al. (1994, above) and Kieny et al.
20 (1988, above), the technical teaching of this literature being incorporated by way of reference into the description of the present invention.

More particularly, it is possible to use, as a source of env gene, all known HIV isolates, in
25 particular those described above. The cloning can be advantageously carried out by the PCR technique, followed by insertion of the DNA fragment into a suitable vector. The cleavage site(s) can then be deleted by site-directed mutagenesis, as described by
30 Kieny et al. (1988, above) or in Example 1 below. The preparation of the vectors, and all the other technical procedures, can be carried out according to the protocols described in the manuals by Sambrook et al. (Molecular Cloning, A Laboratory Manual, Cold Spring
35 Harbor Laboratory Press, U.S.A., 1989).

The expression vector in which the DNA fragment encoding a glycoprotein according to the invention is finally cloned can be a plasmid, a phage, a whole virus

DNA, a cosmid, a DNA intended to integrate into a cell, etc. This vector preferably comprises sequences which regulate the expression of the env gene and, where appropriate, other sequences which regulate the translocation of the glycoprotein towards the membrane of the host producer cell. Host cells which are the most suitable, due to glycosylation which is close, or even identical, to that desired, are higher eukaryotic cells, which can include, for example, immortalized cell lines originating from monkeys (Cos-7, ATCC CRL 1651; Vero76, ATCC CRL 1587), from hamsters (BHK, ATCC CRL 10; CHO, PNAS USA, 77: 4216, 1980), from mice (TM4, Mather, Biol. Reprod., 23, 243-251, 1980), from humans (Hela, ATCC CCL2; WI38, ATCC CCL75; Hep G2; HB 8065), or from dogs (MDCK, ATCC CCL34), etc.

The most suitable expression vectors are those which reproduce in eukaryotes, in particular the vaccinia virus which is well known in the prior art (WO 86/07593), for example.

In a particular embodiment of the present invention, it is possible to produce in particular gp160 molecules according to the teaching described in EP541753 (above), or gp140 molecules according to the method of Earl et al., (1990, above), or even any other glycoprotein variant in which one or more portions of gp41 and/or gp120 will be removed, the objective being that the gp41 portion is sufficient for trimer formation to take place, and that the gp120 portion is sufficient to be recognized by neutralizing anti-gp120 antibodies and by CD4. In order to choose modified env genes which satisfy the needs of the present invention, those skilled in the art are able to proceed step by step or randomly, and then to choose, from the sequences which do not satisfy our needs, those which do satisfy them.

After having produced the glycoprotein by genetic recombination techniques or by HIV infection of cells, it is purified by means of techniques known to

those skilled in the art, in particular those which involve lentil lectins (Pialoux et al., 1995, above; Salmon-Céron et al., 1995, above), those described in WO 91/13906 (above) which can also be optionally adapted to the needs of the present invention, or even those described in Example 1 (immunoaffinity), for example.

With regards to the recombinant proteins, it may be noted that a portion of the glycoproteins thus purified has interchain disulphide bridges, whatever the nature of the host or of the vector used. The glycoproteins associate, in fact, as dimers (a portion being covalent) which are visible on SDS PAGE gel after fixing with a bridging agent. With regards to the glycoproteins purified from HIV infected cells, they are also in the form of tetramers (WO 94/00557, above).

In order to satisfy the needs of the present invention, the glycoproteins are therefore dissociated, and then they are subjected to conditions which promote their natural reassembly, i.e. in the form of trimers. For this, the glycoprotein is subjected to steps which involve at least one reducing agent, one ionic detergent and/or one neutral detergent, under conditions such that a glycoprotein which satisfies the needs of the present invention is obtained.

One or more reducing agent(s) may be chosen from dithiothreitol, β -mercaptoethanol, reduced glutathione or sodium borohydride molecules, for example.

One or more ionic detergent(s) may be chosen from the salts of dodecyl sulphate, in particular sodium dodecyl sulphate (SDS) or lithium dodecyl sulphate, the salts of dioctyl sulphosuccinate (sodium dioctyl sulphosuccinate, for example), the salts of cetyltrimethylammonium (bromium cetyltrimethylammonium, for example), the salts of cetylpyridinium (chlorine cetylpyridinium, for example), the N-dodecyl- or N-tetradecylsulphobetaines, the zwittergents 3-14 and

3-[(3-chloamidopropyl)dimethylamino]-1-propane
sulphonate (CHAPS), for example.

Similarly, one or more neutral detergent(s) may
be chosen from tween20®, tween80®, octylglucoside,
5 laurylmaltoside, hecameg®, lauryldimethylamine,
decanoyl-N-methylglucamide, polyethylene glycol lauryl
ether, triton X100® and Lubrol PX®, for example.

The operating conditions should be sufficient
to dissociate the glycoproteins and reassemble them as
10 trimers. For this, generally, the glycoproteins can be
dissociated using one or more ionic detergent(s), in
the presence or absence of a reducing agent, and then
the reassembly of the monomers can be promoted by
substituting the ionic detergent with a neutral
15 detergent, by means of dialysis, for example. In this
way, the production of a glycoprotein according to the
invention, comprising less than 50% of other protein
contaminants (mainly consisting of covalent dimers), is
ensured.

20 Preferably, in order to obtain exclusively
glycoprotein trimers according to the invention, the
purified glycoproteins are subjected, in the course of
the treatment, to a reducing agent so as to release the
covalent dimers, free sulphydryl functions are, where
25 appropriate, blocked by means of suitable molecules,
for instance alkylating agents such as N-ethylmaleimide
or iodoacetamide, and then the remaining sulphydryl
functions are gently reoxidized in the presence of an
oxidizing agent such as oxidized glutathione, for
30 example.

In a particular embodiment of the present
invention, the purified glycoprotein can be subjected
successively to a reducing agent, to an alkylating
agent, to an oxidizing agent, to an ionic detergent and
35 to dialysis against a neutral detergent, for example.

In another particular embodiment of the present
invention, the purified glycoprotein can be subjected
successively to an ionic detergent, to a reducing

agent, to an oxidizing agent and to dialysis against a neutral detergent.

At the end of the method the neutral detergent can be substituted with a suitable buffer, for example by means of dialysis.

Another subject of the present invention relates to a vaccine comprising the glycoprotein according to the present invention, and an adjuvant. This vaccine can contain, as an HIV surface antigen, only the glycoprotein according to the present invention, the dimeric or monomeric forms of a gp160 or gp120 being specifically excluded, for example, for reasons of reduced immunogenicities. Other valences concerning other diseases can also be added to this vaccine, the amounts of antigens and/or the formulation of each valence probably having, however, to be optimized so as to ensure an effective immune response, for example. The valences of other pathogens can originate from bacteria, from viruses or from parasites, for example those causing hepatitis (types A to G), measles, mumps, polio, tuberculosis, diphtheria, malaria, etc.

Among the adjuvants which can be used, it is possible to list all the aluminium salts, such as the aluminium phosphates and hydroxides; Freund's adjuvant; N-acetylmuramyl-L-alanyl-D-isoglutamyl-L-alanine-2-[1,2-dipalmitoyl-sn-glycero-3-(hydroxyphosphoryloxy)] (see Sanchez-Pescador et al., J. Immu., 141, 1720-1727, 1988); the molecules derived from *Quillaja saponaria*, such as Stimulon® (Aquila, US); the Iscoms® (CSL Ltd, US); all molecules based on cholesterol and analogues, such as DC Chol® (Targeted Genetics); the glycolipid Bay R1005® (Bayers, DE); the antigens of *Leishmania brasiliensis*, such as LeIF (technical name) available from Corixa Corp. (US), the polymers of the polyphosphazene family, such as Adjumer (technical name) available from the "Virus Research Institute" (US).

The vaccine compositions according to the invention can be used for preventing HIV-1 infections, the dose and the route and frequency of administration probably having, however, to be optimized so as to obtain an effective immune response.

A final subject of the present invention relates to the use of the glycoprotein according to the invention in the implementation of any method for diagnosing, *in vitro*, infections caused by HIV.

Other characteristics of the present invention will become apparent in the course of the following descriptions of examples of embodiments, which are provided for the purposes of illustrating the present invention and which are not intended to be limiting.

The manipulation of the cells, the preparation of the vectors, the transformation of cells and all the other technical procedures are, where not otherwise specified, carried out according to the protocols described in the manual by Sambrook et al. (1989, above). These examples are preceded by a brief description of Figure 1 and of the methods measuring the affinity of gp160 for CD4.

Demonstration of an affinity for CD4 by radio-immune precipitation: a recombinant CD4 labelled with sulphur 35, produced by CHO cells (Genentech, USA; VanCott et al., 1995, above), is used. Coprecipitation experiments are then carried out, during which the CD4 is added, in an increasing amount, to a fixed amount of purified gp160 in trimeric form in order to determine the saturation point, and then they are coprecipitated with an anti-gp160 antiserum. For this, the CD4 and the gp160 are mixed for 1 h at 4°C, the antibody (OKT4, Ortho Diagnostics, US) antibody is added, and the complexes are washed and separated by electrophoresis.

Demonstration of an affinity for CD4 by ELISA: the measurement of the affinity constants of CD4 for the

glycoprotein according to the invention is carried out using the technique of Friguet et al. (J. of immunological methods, 77, 305-319, 1985).

5 Measurement of the affinity of the gp120 on CD4 by
surface plasmon resonance: the Biacore® is a machine
for analysing biospecific interactions in real time and
without labelling, which uses the principle of surface
plasmon resonance. During the analysis, one of the
10 interacting components (the ligand) is coupled to a
hydrophilic (dextran) or hydrophobic (HPA surface)
matrix. The other interacting component (analyte)
passes in contact with the surface via a microfluid
transfer cartridge. The increase in mass close to the
15 surface due to the interaction between the molecules is
represented as a function of time on a sensorgram.
Various types of coupling chemistry allow for the
attachment of practically all the biomolecules to the
matrix. The user therefore creates a biospecific
20 surface which is tailor-made for each type of
application. In practice, the glycoprotein according to
the invention is coupled to the matrix and various
concentrations of CD4 are sent, by the machine, into
contact with this matrix. Each time, the mass of CD4
25 attached to the glycoprotein is recorded. The Biaeval3®
software automatically calculates the dissociation
constant of the CD4 on the gp120.

Figure 1: representation of the SDS PAGE analysis under
30 reducing conditions, obtained with the gp160 produced
by VVTG9150, purified, treated to make trimers and
attached using a bridging agent (col. 3 and 4); in
comparison with that obtained under reducing conditions
with the gp160 produced by VVTG9150, purified and
35 directly attached (col. 2); in comparison with that
obtained under reducing conditions with monomers of
gp160 (col. 5 and 6); and in comparison with that

obtained under nonreducing conditions with the gp160 produced by VVTG9150 and purified (col. 7).

Example 1

5 A recombinant vector based on the vaccinia virus, VVTG9150, is used for the production of gp160. The construction of the plasmid for transferring the gene encoding the hybrid env protein HIV-1_{MN/LAI} into the genome of the vaccinia virus VVTG9150 is described
10 below.

 The *Pst*I-*Kpn*I DNA fragment of pTG1163, ref. Kieny et al. (Prot. Eng., 2, 219-225, 1998), which contains the sequence encoding the signal peptide and the first amino acids of the gp120 of the HIV-1_{LAI} virus, is inserted at the *Pst*I and *Kpn*I sites of the
15 bacteriophage M13TG130, ref. Kieny et al. (Gene, 26, 91-99, 1983), generating M13TG4147. The *Pst*I-*Pst*I fragment of pTG1163, containing all of the gene encoding a gp160/soluble of HIV-1_{LAI}, is introduced into
20 the *Pst*I restriction site of M13mp70, generating M13TG4137. The DNA of the bacteriophage M13TG4137 is then cleaved with *Bgl*III, digested with polymerase I (Klenow fragment) in order to generate a blunt end, and then cleaved with *Eco*RI, in order to be inserted at the
25 *Eco*RV and *Eco*RI sites of the bacteriophage M13TG4147, generating M13TG4158. A deletion is then produced on M13TG4158, with an oligonucleotide, which allows the introduction of an *Sph*I site and of an *Sma*I site. The bacteriophage M13TG4168 is obtained. The gene encoding
30 gp120_{MN} is then amplified from DNA of SupT1 cells infected with the HIV-1_{MN} virus, by the PCR technique with oligonucleotides which introduce *Sph*I and *Sma*I sites, respectively. The amplified DNA fragment is then digested with *Sph*I and *Sma*I and inserted at the
35 corresponding sites of M13TG4168, generating M13TG4174. Site-directed mutagenesis is carried out on M13TG4174 with an oligonucleotide which makes it possible to mutate a potential transcription stop site (TTTTTNT)

recognized by the vaccinia virus in the early genes, and to introduce an *EcoRI* restriction site, thus generating M13TG8120. The *PstI*-*PstI* fragment of M13TG8120 is then cloned into the *PstI* site of the plasmid pTG9148, generating pTG9150 (the virus VVTG9150 after transfection).

pG9148 is, moreover, generated in the same way: the sequence corresponding to the H5R promoter of the vaccinia virus is amplified by the PCR technique with oligonucleotides which introduce *BamHI* and *BglII* sites, respectively. The amplified DNA fragment is then digested with *BglII* and *BamHI* and inserted at the corresponding sites of M13TG6131 (Gene, 26, 91-99, 1983), generating M13TG8124. The *BamHI*-*BglII* fragment of M13TG8124 containing the H5R promoter sequence is introduced into the *BamHI* restriction site of pTG9133, generating pTG9145. The plasmid pTG9133 was constructed by introducing a *BamHI* site between the *ClaI* and *EcoRI* sites of pTG1H-TK (Nature, 312, 5990, 163-166, 8 Nov. 1984), by ligating an OTG4451/OTG4452 linker. A multiple cloning site derived from M13TG131 digested with *BglII* and *EcoRI* is introduced into the *BamHI* and *EcoRI* sites of pTG9145, generating pTG9148.

In conclusion, VVTG9150 therefore encodes a hybrid and soluble gp160 in which the gp120 portion derives from HIV-1MN, and the gp41 transmembrane portion originates from an LA1 isolate. Several modifications are also introduced into this coding sequence. Firstly, an *SphI* restriction site is created immediately downstream of the sequence encoding the signal peptide, without modifying the amino acid sequence. Secondly, a *SmaI* restriction site is created immediately above the cleavage sequence between the gp120 and the gp41, without modifying the amino acid sequence. Thirdly, the two cleavage sites at position 507-516 (amino acid numbering in accordance with Myers et al., in: Human retroviruses and AIDS, Los Alamos Nat. Lab., USA, 1994) are mutated (original sequence

KRR...REKR mutated to QNH...QEHN). Fourthly, the sequence encoding the hydrophobic transmembrane peptide IFIMIVGGLVGLRIVFAVLSIV (amino acids 689-710 of Myers et al.) is deleted. Fifthly, a stop codon has been substituted for the second E codon encoding PEGIEE (amino acids 735-740 of Myers et al.), i.e. the 29th amino acid of the intracytoplasmic domain.

VVTG9150 is then propagated in order to produce the hybrid gp160 on BHK21 cells, under conventional conditions (Nature, 312, 163-166, 1984).

The hybrid gp160 glycoprotein is then purified successively by ion exchange chromatographies, immunoaffinity chromatography, gel filtration, and concentration. In summary, the culture medium containing the gp160 is passed successively through two DEAE Trisacryl LS Plus® supports, equilibrated in BPG200® and BPG100® columns (Pharmacia) with a pH 8.3 buffer containing 2.42 g/l of Tris and 1 ml/l of triton X100. Then, the elution fractions containing the gp160 are passed through an AF-Tresyl Toyopearl® (Tosoh Corp, JP) onto which the antibody IAM5F3 has been grafted (publication?) and which has been equilibrated in a buffer composed of 29.22 g/l of NaCl, 2.42 g/l of Tris and 1 ml/l of triton X100. The elution is collected as soon as the increase in OD is seen on the display, this collection being until return to base line. The pH of the elution is then neutralized with 4% (v:v) of 2M Tris HCl buffer. The neutralized elution is subjected to gel filtration in an XK 50/100® column containing the sephacryl HR S300 support equilibrated in a PBS buffer. If the protein concentration is then lower than 0.44 mg/ml, the elution is concentrated in an Amicon® cell equipped with a YM30 membrane. Then, the elution or the concentrate is inactivated in a water bath at 60°C for 1 h, and it is filtered (0.22 µm) in a Nalgene® flask. It is thus possible to obtain approximately 1.34 mg/ml of gp160 which is 91% pure (visualized on SDS PAGE).

Starting with 560 μ l of purified gp160 (1 mg/ml), 65 μ l of 1M sodium phosphate buffer, pH 7.8; 5.5 μ l of distilled water and 19.5 μ l of 250 mM dithiothreitol (DTT) are added, and the mixture is
5 vortexed for 15 s. 51.5 μ l of 1M sodium phosphate (NaH_2PO_4), are added, then the sulphhydryl groups are blocked by adding 95 μ l of 100 mM N-ethylmaleimide, the mixture is incubated for 15 min, the sulphhydryl groups are reoxidized by adding 32.5 μ l of reduced glutathione
10 at 150 mM and 484 μ l of oxidized glutathione at 100 mM, and the mixture is incubated for 30 min. The gp160 dimers are then dissociated by adding 13.2 μ l of sodium dodecyl sulphate (SDS) at 10%. The sample is placed in a dialysis cassette with a volume of 3 ml, against 3 l
15 of PBS buffer with 10 mM of octylglucoside. The dialysis is carried out overnight at room temperature with gentle stirring. The detergent is finally eliminated by one or more new dialyses against PBS buffer. The gp160 molecules thus treated are
20 exclusively in the form of trimers.

Figure 1 represents the SDS PAGE analysis under reducing conditions (DTT), obtained with the gp160 produced by VVTG9150, purified, treated to make trimers and attached using the bifunctional bridging agent
25 ethylene glycol-bis(succinimidyl succinate) (EGS) (col. 3 and 4); in comparison with that obtained under reducing conditions with the gp160 produced by VVTG9150, purified and directly attached using the EGS (col. 2: dimers); and in comparison with that obtained
30 under reducing conditions with monomers of gp160 (col. 5 and 6); and in comparison with that obtained under nonreducing conditions with the gp160 produced by VVTG9150 and purified (col. 7: in the absence of a reducing agent, the interchain linkages lead to the
35 formation of dimers, trimers and tetramers).

Example 2

Using the vaccinia virus, a gp120 which is extended by the first 129 amino acids of the N-terminal portion of gp41, as described by Earl et al., Proc. Natl. Acad. Sci. USA, 87, 648-652, 1990, is expressed. In so far as the gp41 portion is limited to its first 129 amino acids, it does not comprise a transmembrane region. This glycoprotein exhibits, on SDS PAGE gel, a molecular weight of the order of 140 kD and is commonly termed gp140.

This gp140 is purified successively by ion exchange chromatography, affinity chromatography with lentil lectins, and by gel filtration, as described by Pialoux et al. (1995, above) and Salmon-Céron et al. (1995, above).

Starting with 100 μ l of purified gp140 (1 mg/ml), 2 μ l of 250 mM dithiothreitol (DTT) and 10 μ l of SDS (10%) are added, the mixture is incubated for 15 min, 20 μ l of oxidized glutathione (250 mM) are added to it, it is incubated overnight at 4°C, and then the sample is placed in a dialysis cassette with a volume of 3 ml, against 3 l of PBS buffer containing 10 mM of octylglucoside. The dialysis is carried out overnight at room temperature with gentle stirring. The detergent is finally eliminated by one or more new dialyses against PBS buffer. Against all expectations, this method makes it possible to eliminate all the interchain disulphide bridges without it being necessary to block the sulphhydryl groups with an alkylating agent. The gp140 molecules thus treated are exclusively in the form of trimers.

Example 3

Using the vaccinia virus, a gp160 as described by Kieny et al. (Protein Engineering, 2, 219-225, 1988) is expressed. It is purified as described in Example 1 and then treated with SDS, and it is dialysed against a PBS buffer containing 10 mM of octylglucoside. After

treatment, a mixture of noncovalent trimers and of covalent dimers of the gp160 is obtained, the predominant form consisting of trimers.

Claims


1. Purified recombinant glycoprotein which satisfies the following properties:
- 5 a) a capacity for adhesion to CD4;
b) an affinity with an anti-gp120 antibody capable of neutralizing HIV infection of cells, *in vitro*;
c) an affinity with an anti-gp41 antibody;
- 10 d) a trimeric form lacking interchain disulphide bridges.
2. Glycoprotein according to Claim 1, characterized in that the glycoprotein is composed of all or part of gp160.
- 15 3. Glycoprotein according to Claim 1, characterized in that it comprises less than 50% of other protein contaminants.
4. Glycoprotein according to Claim 1, characterized in that the capacity for adhesion to CD4
- 20 is at least identical to that of a gp120 of an infectious HIV.
5. Vaccine comprising the purified glycoprotein according to Claim 1, and an adjuvant.
6. Vaccine according to Claim 4, characterized in
- 25 that it contains, as an HIV surface antigen, only the glycoprotein according to Claim 1.
7. Method for obtaining a glycoprotein according to Claim 1, in which, by means of genetic recombination techniques, a glycoprotein satisfying the properties
- 30 a), b) and c) set out in Claim 1 is expressed, purified and subjected to steps involving at least one reducing agent, one ionic detergent and/or one neutral detergent, under conditions such that a glycoprotein satisfying the conditions set out in Claim 1 is
- 35 obtained.
8. Method according to Claim 7, characterized in that the purified glycoprotein is subjected successively to a reducing agent, to an alkylating

agent, to an oxidizing agent, to an ionic detergent and to dialysis against a neutral detergent.

9. Method according to Claim 7, characterized in that the purified glycoprotein is subjected
5 successively to an ionic detergent, to a reducing agent, to an oxidizing agent and to dialysis against a neutral detergent.

10. Use of the glycoprotein according to Claim 1 in the implementation of a method for diagnosing, in
10 vitro, infections caused by HIV.

Figure 1



DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Trimer of HIV *env* Gene Expression Product

the specification of which is attached hereto unless the following space is checked:

☒ was filed on **January 25, 2001** as United States Application Serial Number **09/744,659**.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s):

	<u>Number</u>	<u>Country</u>	<u>Day/Month/Year Filed</u>
1.	98/10,027	France	31/07/1998
2.			

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

	<u>Application Number</u>	<u>Filing Date</u>
1.		
2.		

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

	<u>Application Number</u>	<u>Filing Date</u>	<u>Status: patented, pending, abandoned</u>
1.	PCT/FR99/01871	29/07/1999	Abandoned
2.			

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and I direct that all correspondence be addressed to that Customer Number.

Customer Number: **020306**

Principal attorney or agent: **Michael S. Greenfield**

Telephone number: 312-913-0001

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: **Michel Chevalier**

Inventor's signature: 

Date: **03/20/07**

Residence: **19, rue de la Guillotière, F-38270, Beaurepaire, France**

Citizenship: **A Citizen of France**

Post Office Address: **19, rue de la Guillotière, F-38270, Beaurepaire, France**

FRX